InspireMD (NYSE:NSPR) Trading Down 6.7% - What's Next?

Key Points

• Shares fell 6.7% to $1.39 on Tuesday, trading as low as $1.38 on light volume (15,207 shares) and sitting below the 50‑day and 200‑day moving averages of $1.69 and $1.91.
• Analysts show a consensus Buy rating (three buy ratings) with an average price target of $5.00, including individual targets of $6.00 and $5.00, implying substantial upside from the current price.
• Insiders sold shares last quarter — including a 17,593‑share sale by Shane Thomas Gleason — though insiders still own 34.06% of the company and institutional investors own 44.78%.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) was down 6.7% on Tuesday . The stock traded as low as $1.38 and last traded at $1.39. Approximately 15,207 shares were traded during trading, a decline of 56% from the average daily volume of 34,694 shares. The stock had previously closed at $1.49.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on NSPR shares. Lake Street Capital reissued a "buy" rating on shares of InspireMD in a research report on Tuesday, February 24th. Maxim Group started coverage on InspireMD in a research report on Monday, February 2nd. They set a "buy" rating and a $6.00 target price on the stock. Finally, Loop Capital set a $5.00 target price on InspireMD in a research report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $5.00.

InspireMD Stock Down 6.7%

The company has a market cap of $65.05 million, a price-to-earnings ratio of -1.85 and a beta of 0.95. The firm has a 50-day simple moving average of $1.69 and a 200 day simple moving average of $1.91.

Insider Buying and Selling

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of InspireMD stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $1.62, for a total transaction of $28,500.66. Following the transaction, the insider owned 1,174,664 shares of the company's stock, valued at $1,902,955.68. The trade was a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 61,194 shares of company stock worth $99,188 over the last quarter. Insiders own 34.06% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in InspireMD during the fourth quarter worth approximately $30,000. Virtu Financial LLC acquired a new position in InspireMD during the fourth quarter worth approximately $31,000. Creative Planning acquired a new position in InspireMD during the second quarter worth approximately $44,000. Legato Capital Management LLC acquired a new position in InspireMD during the fourth quarter worth approximately $48,000. Finally, Uniting Wealth Partners LLC purchased a new position in shares of InspireMD in the 3rd quarter valued at approximately $51,000. Institutional investors and hedge funds own 44.78% of the company's stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company's core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company's flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.